Compare Dollar General Corp. (DG) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar General Corp. vs BIO-TECHNE Corp — how do they compare? Dollar General Corp. trades at $119.27 (market cap $27.23B), while BIO-TECHNE Corp trades at $71.23 (market cap $11.12B). The key difference: Dollar General Corp. is far larger — about 2.4× BIO-TECHNE Corp's market cap, and Dollar General Corp. pays the higher dividend (1.91%). Which is the better fit depends on your goals.
| DG | TECH | |
|---|---|---|
Market Cap | $27.23B | $11.12B |
Sector | Consumer Staples | Health |
52-Week High | $156.26 | $71.38 |
52-Week Low | $95.94 | $43.31 |
Enterprise Value | $41.67B | $11.20B |
Dividend Yield | 1.91% | 0.45% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
